Purchases and Sales Made in Q3 2024 in Kymera Therapeutics, Inc. (KYMR)
This table provides information about the institutional ownership of Kymera Therapeutics, Inc. (KYMR) during Q3 2024. The information is specifically focused on institutions that hold shares of Kymera Therapeutics, Inc..
| Report Date | Institution (Fund) | Operation | Option | Shares change | Value Range | Shares Held | Trade History |
|---|---|---|---|---|---|---|---|
|
Nov 14, 2024
Q3 2024
|
Redmile Group, LLC
San Francisco, CA |
SELL
|
- |
-186K- 11.78% |
$5.61M - $9.75M
|
1.39M
$51.3M
|
|
|
Nov 14, 2024
Q3 2024
|
Goldman Sachs Group Inc
New York, NY |
SELL
|
- |
-237K- 51.37% |
$7.16M - $12.4M
|
225K
$8.28M
|
|
|
Nov 14, 2024
Q3 2024
|
Marshall Wace, LLP
London, X0 |
SELL
|
- |
-259K- 68.75% |
$7.81M - $13.6M
|
118K
$4.33M
|
|
|
Nov 12, 2024
Q3 2024
|
Atlas Venture Life Science Advisors, LLC
|
SELL
|
- |
-454K- 8.48% |
$13.7M - $23.8M
|
4.9M
$180M
|
|
|
Nov 14, 2024
Q3 2024
|
Deep Track Capital, LP
Greenwich, CT |
SELL
|
- |
-900K- 59.98% |
$27.1M - $47.1M
|
600K
$22.1M
|